
Biogen Idec and Isis Pharmaceuticals have entered their fourth partnership in two years in a deal that will see the …

Rival MS treatments from Biogen Idec and Genzyme have both received European approval. The CHMP has recommended marketing authorisation for …

Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …
Biogen Idec has a new head of research and development, appointing Douglas Williams to oversee its global operations. The position …
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

